Agenda - Practical Recommendations in Immuno and Molecular Oncology (PRIMO)

The 2021 Annual
PRIMO Meeting Agenda

The PRIMO meeting Co-Chairs and Steering Committee worked hard to curate an agenda to meet the educational needs of all attendees and focused on the following key areas:
  • Practical considerations of applying biomarkers and targeted therapy
  • Integration of immunotherapy, with a focus on novel management approaches
  • Patient selection, as well as timing and sequencing of therapy
  • Dealing with important trends, such as big data and defining value in cancer care
NOTE: All times listed are in Central Standard Time (CST)
3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now (Non-CME/CE)
3:05 PM – 3:10 PM
History of Women in Oncology (Non-CME/CE)
3:10 PM – 3:20 PM
Conference Overview and Objectives
Hematologic Malignancies - Julie Vose  /  Sagar Lonial
3:20 PM – 3:40 PM
Indolent and Aggressive NHL Including CAR-T
3:40 PM – 4:00 PM
Smoldering MM and Early Therapy vs Observation
4:00 PM – 4:20 PM
AML/MDS: Update on Therapy
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
Hematologic Malignancies (cont.)
5:20 PM – 5:40 PM
CLL: What is the Best Initial Therapy for a Newly Diagnosed patient?
5:40 PM – 6:00 PM
Update on ALL Therapy
6:00 PM – 6:20 PM
Break I Visit the Virtual Exhibits
Gastrointestinal Malignancies – Rachna T. Shroff
6:20 PM – 6:40 PM
Colon Cancer - Divide and Conquer
6:40 PM – 7:00 PM
Hot Topics in Pancreatic and Biliary Cancer
7:00 PM – 7:20 PM
Five Years In; How Far Reaching Have Biosimilars Been in the US?
Product Theater
7:20 PM – 8:20 PM
Product Theater (Non-CME/CE)
Closing Remarks
8:20 PM – 8:25 PM
Close of meeting day 1

3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now (Non-CME/CE)
3:05 PM – 3:10 PM
History of Women in Oncology (Non-CME/CE)
3:10 PM – 3:20 PM
Conference Overview and Objectives
Melanoma, Skin Cancers, RCC – Shane Morita
3:20 PM – 3:40 PM
Melanoma: Keeping Up With the Data
3:40 PM – 4:00 PM
Sarcoma: Where are We Making Progress?
4:00 PM – 4:20 PM
Medical Therapy for Head and Neck Cancers: Current Status
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
GU Cancers - Sanjiv Agarwala
5:20 PM – 5:40 PM
Bladder Cancer: Sequencing Therapeutic Choices
5:40 PM – 6:00 PM
RCC: A Surfeit of Riches – What’s a Clinician to Do?
6:00 PM – 6:20 PM
Impact of COVID-19 on Cancer Care
6:20 PM – 6:40 PM
Break I Visit the Virtual Exhibits
Lung - Paul A. Bunn
6:40 PM – 7:00 PM
Immunotherapy for Advanced NSCLC.
7:00 PM – 7:20 PM
Matching Drugs to Targets in NSCLC
7:20 PM – 7:40 PM
Therapeutic Advances in SCLC
Product Theater
7:40 PM – 8:40 PM
Product Theater (Non-CME/CE)
Closing Remarks
8:40 PM – 8:45 PM
Close of meeting day 2

3:00 PM – 3:05 PM
Meeting Welcome from Cancer Expert Now (Non-CME/CE)
3:05 PM – 3:10 PM
History of Women in Oncology (Non-CME/CE)
3:10 PM – 3:20 PM
Conference Overview and Objectives
Breast Cancer – Hope S. RugoHope S. Rugo, MD
3:20 PM – 3:40 PM
New Directions in the Treatment of ER+ Breast Cancer
3:40 PM – 4:00 PM
Updates in the Treatment of HER2+ Breast Cancer
4:00 PM – 4:20 PM
Triple Negative Breast Cancer: Immunotherapy and Novel Agents
Product Theater
4:20 PM – 5:20 PM
Product Theater (Non-CME/CE)
Breast Cancer (CONT.)
5:20 PM – 5:40 PM
Managing the Toxicity of Endocrine Therapy: Diet, Exercise, Sexual Health
5:40 PM – 6:00 PM
Genomics to Guide Therapy in Early and Late Stage Breast Cancer
Hope S. Rugo, MD
6:00 PM – 6:20 PM
Metastatic Survivorship Care
6:20 PM – 6:40 PM
SITC on Practical Recommendations Including Reimbursement Issues for Immunotherapy
6:40 PM – 7:00 PM
Break | Visit the Virtual Exhibits
Other Women’s Cancers
7:00 PM – 7:20 PM
Ovarian Cancer: PARP, Bevacizumab, Immunotherapy
7:20 PM – 7:40 PM
Cervical and Uterine Cancer Updates
Closing Remarks
7:40 PM – 7:50 PM
Closing Remarks

We acknowledge commercial support from Taiho Oncology, Exelixis, Pfizer, AstraZeneca, and Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.